Pharmaceutical developer Advanced Magnetics of Cambridge, MA, has signed a research agreement to develop new nucleoside therapeutic drugs with the University of Minnesota in Minneapolis. Under the deal, Advanced Magnetics over the next three years will
Pharmaceutical developer Advanced Magnetics of Cambridge, MA, has signed a research agreement to develop new nucleoside therapeutic drugs with the University of Minnesota in Minneapolis. Under the deal, Advanced Magnetics over the next three years will sponsor research led by Dr. Carston Wagner to develop drug candidates with anti-viral or anti-tumor characteristics. The deal is part of the companys plan to diversify from its core MRI contrast agent market (SCAN 3/18/98).
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.